Study populations included a mix of non-metastatic and biochemically recurrent prostate cancer patients, with high-risk features such as elevated prostate-specific antigen (PSA) levels (≥20 ng/mL), Gleason score ≥ 8, and/or T3-T4 staging. The gene discussed is KLK3; the disease is prostate carcinoma.